Industrializing iPSC-Based Cell Therapies
Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population. The cell banks meet major regulatory agency requirements and the iPSC lines and corresponding donor tissue undergo extensive characterization.